You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 1477 First efficacy and multi-omic analysis data from phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma

Citation Tools

Article menu

Download PDFPDF

Late-Breaking Abstracts
Clinical Trials In Progress
1477 First efficacy and multi-omic analysis data from phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Wen P, Duault C, Gonzalez-Kozlova E, et al
1477 First efficacy and multi-omic analysis data from phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma
Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.1477